Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.7% – What’s Next?
by Amy Steele · The Cerbat GemDyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) shares fell 6.7% during trading on Friday . The company traded as low as $18.42 and last traded at $18.2590. 544,809 shares traded hands during trading, a decline of 82% from the average session volume of 3,054,985 shares. The stock had previously closed at $19.56.
Analyst Ratings Changes
Several analysts have recently issued reports on the company. Robert W. Baird set a $30.00 price target on Dyne Therapeutics in a research note on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, October 8th. Sanford C. Bernstein set a $23.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, December 9th. Chardan Capital restated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. lowered their target price on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, November 14th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $38.47.
Get Our Latest Research Report on Dyne Therapeutics
Dyne Therapeutics Stock Performance
The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.14. The firm has a 50-day moving average of $20.39 and a 200 day moving average of $14.88. The stock has a market capitalization of $2.61 billion, a P/E ratio of -5.00 and a beta of 1.32.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05. Research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.
Institutional Trading of Dyne Therapeutics
Several hedge funds have recently modified their holdings of DYN. JPMorgan Chase & Co. raised its position in Dyne Therapeutics by 9.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after purchasing an additional 278,466 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Dyne Therapeutics in the third quarter valued at about $147,000. Jacobs Levy Equity Management Inc. acquired a new stake in Dyne Therapeutics in the 3rd quarter valued at about $9,230,000. Armistice Capital LLC raised its stake in shares of Dyne Therapeutics by 19.7% in the third quarter. Armistice Capital LLC now owns 3,064,000 shares of the company’s stock worth $38,760,000 after acquiring an additional 504,000 shares during the last quarter. Finally, TCG Crossover Management LLC lifted its position in shares of Dyne Therapeutics by 22.5% during the third quarter. TCG Crossover Management LLC now owns 4,615,144 shares of the company’s stock worth $58,382,000 after purchasing an additional 848,484 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.